{"id":"NCT04839562","sponsor":"Massachusetts General Hospital","briefTitle":"A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults","officialTitle":"Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-08-06","primaryCompletion":"2023-01-27","completion":"2023-01-27","firstPosted":"2021-04-09","resultsPosted":"2024-03-04","lastUpdate":"2024-03-04"},"enrollment":66,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"Solriamfetol 75 MG","otherNames":["Sunosi 75 mg"]},{"type":"DRUG","name":"Solriamfetol 150 MG","otherNames":["Sunosi 150 mg"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"solriamfetol","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.","primaryOutcome":{"measure":"Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score","timeFrame":"six weeks","effectByArm":[{"arm":"Solriamfetol","deltaMin":-7.6,"sd":null},{"arm":"Placebo","deltaMin":-2.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=.0106"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37819836"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":["Cold/Infection/Allergy","Headache","Insomnia","Musculoskeletal","Nausea/Vomiting/Diarrhea (Gastrointestinal)"]}}